Multi-Centre Study of Progression Factors and Intravesical Recurrence in Patients with Urothelial Carcinoma of the Upper Urinary Tract

被引:0
作者
Garcia-Morales, Lucia [1 ]
Contreras-Matos, Francisco Javier [2 ]
Blanca-Pedregosa, Ana [1 ]
Mellado-Castillero, Alejandro [3 ]
Campos-Hernandez, Juan Pablo [1 ]
Lara, Maria Fernanda [4 ]
Puche-Sanz, Ignacio [2 ]
Gomez-Gomez, Enrique [1 ]
机构
[1] Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba IMIB UCO, Urol Dept, Avda Menendez Pidal S-N, Cordoba 14004, Spain
[2] Virgen Nieves Univ Hosp, Biosanit Res Inst Granada IBS, Dept Urol, Granada 18071, Spain
[3] Inst Urol Surg, Malaga 29007, Spain
[4] Univ Malaga UMA, Fac Med, IBIMA, BIONAND, Malaga 29010, Spain
关键词
urothelial carcinoma; disease progression; intravesical recurrence; risk factors; RADICAL NEPHROURETERECTOMY; BLADDER; IMPACT; PROGNOSIS;
D O I
10.3390/diagnostics14222491
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: A retrospective analysis was conducted to identify factors associated with disease progression and intravesical recurrence (IVR) in a multi-centre cohort of patients with upper urinary tract urothelial carcinoma (UTUC) treated surgically between 2015 and 2021. Methods: Progression-free survival (PFS) and IVR-free survival were evaluated using a Kaplan-Meier survival curve and a Log-Rank test. Prognostic factors for progression and IVR were analysed using Cox logistic regression analysis. Results: A total of 170 patients were analysed. Up to 32.9% developed progression within 65.64 +/- 3.44 months. Multivariate analysis showed that pT (HR 2.9, 95%CI 1.54-5.48, p = 0.01), margin status (HR 2.89, 95%CI 2.88-57.68, p = 0.01), and lymphovascular involvement (HR 7.97, 95% CI 1.43-44.42, p = 0.02) were independent risk factors for PFS. Up to 25.9% of patients presented with IVR at a mean time of 68.33 +/- 3.59 months. A previous diagnosis of bladder cancer (BC) (HR 3.73, 95% CI 1.24-11.22, p = 0.02) and the non-invasive appearance of the tumour on computed tomography were significant risk factors for IVR (HR 0.23, 95% CI 0.05-0.95, p = 0.03). Conclusions: pT stage, margin involvement, and lymphovascular involvement were independent risk factors for UTUC progression. The main risk factor for presenting with IVR after UTUC was a previous diagnosis of BC.
引用
收藏
页数:9
相关论文
共 26 条
  • [1] Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study
    Almas, Bjarte
    Halvorsen, Ole J.
    Johannesen, Tom Borge
    Beisland, Christian
    [J]. WORLD JOURNAL OF UROLOGY, 2021, 39 (09) : 3385 - 3391
  • [2] Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
    Birtle, Alison
    Johnson, Mark
    Chester, John
    Jones, Robert
    Dolling, David
    Bryan, Richard T.
    Harris, Christopher
    Winterbottom, Andrew
    Blacker, Anthony
    Catto, James W. F.
    Chakraborti, Prabir
    Donovan, Jenny L.
    Elliott, Paul Anthony
    French, Ann
    Jagdev, Satinder
    Jenkins, Benjamin
    Keeley, Francis Xavier, Jr.
    Kockelbergh, Roger
    Powles, Thomas
    Wagstaff, John
    Wilson, Caroline
    Todd, Rachel
    Lewis, Rebecca
    Hall, Emma
    [J]. LANCET, 2020, 395 (10232) : 1268 - 1277
  • [3] Adjuvant Systemic Therapy Improved Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
    Di Bello, Francesco
    Jannello, Letizia Maria Ippolita
    Siech, Carolin
    de Angelis, Mario
    Penaranda, Natali Rodriguez
    Tian, Zhe
    Goyal, Jordan A.
    Ruvolo, Claudia Colla
    Califano, Gianluigi
    Creta, Massimiliano
    Morra, Simone
    Saad, Fred
    Shariat, Shahrokh F.
    de Cobelli, Ottavio
    Briganti, Alberto
    Chun, Felix K. H.
    Puliatti, Stefano
    Longo, Nicola
    Karakiewicz, Pierre I.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (10) : 7229 - 7236
  • [4] Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma
    Hwang, Eu Chang
    Sathianathen, Niranjan J.
    Jung, Jae Hung
    Kim, Myung Ha
    Dahm, Philipp
    Risk, Michael C.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (05):
  • [5] Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy
    Ishioka, Junichiro
    Saito, Kazutaka
    Kijima, Toshiki
    Nakanishi, Yasukazu
    Yoshida, Soichiro
    Yokoyama, Minato
    Matsuoka, Yoh
    Numao, Noboru
    Koga, Fumitaka
    Masuda, Hitoshi
    Fujii, Yasuhisa
    Sakai, Yasuyuki
    Arisawa, Chizuru
    Okuno, Tetsuo
    Nagahama, Katsuhi
    Kamata, Shigeyoshi
    Sakura, Mizuaki
    Yonese, Junji
    Morimoto, Shinji
    Noro, Akira
    Tsujii, Toshihiko
    Kitahara, Satoshi
    Gotoh, Shuichi
    Higashi, Yotsuo
    Kihara, Kazunori
    [J]. BJU INTERNATIONAL, 2015, 115 (05) : 705 - 712
  • [6] Clinical practice patterns for upper tract urothelial carcinoma: a nationwide survey in Japan
    Kikuchi, Eiji
    Oya, Mototsugu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (08) : 768 - 774
  • [7] Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial
    Kleinmann, Nir
    Matin, Surena F.
    Pierorazio, Phillip M.
    Gore, John L.
    Shabsigh, Ahmad
    Hu, Brian
    Chamie, Karim
    Godoy, Guilherme
    Hubosky, Scott
    Rivera, Marcelino
    O'Donnell, Michael
    Quek, Marcus
    Raman, Jay D.
    Knoedler, John J.
    Scherr, Douglas
    Stern, Joshua
    Weight, Christopher
    Weizer, Alon
    Woods, Michael
    Kaimakliotis, Hristos
    Smith, Angela B.
    Linehan, Jennifer
    Coleman, Jonathan
    Humphreys, Mitchell R.
    Pak, Raymond
    Lifshitz, David
    Verni, Michael
    Adibi, Mehrad
    Amin, Mahul B.
    Seltzer, Elyse
    Klein, Ifat
    Konorty, Marina
    Strauss-Ayali, Dalit
    Hakim, Gil
    Schoenberg, Mark
    Lerner, Seth P.
    [J]. LANCET ONCOLOGY, 2020, 21 (06) : 776 - 785
  • [8] The Impact of Primary Tumor Location on Long-Term Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
    Krajewski, Wojciech
    Nowak, Lukasz
    Malkiewicz, Bartosz
    Chorbinska, Joanna
    Kielb, Pawel
    Poterek, Adrian
    Sporniak, Bartlomiej
    Sut, Michal
    Moschini, Marco
    Lonati, Chiara
    Carando, Roberto
    Teoh, Jeremy Yuen-Chun
    Mori, Keiichiro
    Kaliszewski, Krzysztof
    Szydelko, Tomasz
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):
  • [9] Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract
    Lee, Ji Yun
    Kim, Kyung
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Lee, Hyun Moo
    Choi, Han-Yong
    Kwon, Ghee-Young
    Kim, Kyoung-Mee
    Lee, Jeeyun
    Lim, Ho Yeong
    Park, Se Hoon
    [J]. TRANSLATIONAL ONCOLOGY, 2018, 11 (01): : 37 - 42
  • [10] The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma
    Li, Hailong
    Zhou, Jie
    Chen, Renfu
    Zhu, Jiawei
    Wang, Junqi
    Wen, Rumin
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (08) : 356e1 - 356e9